The inhibitory effects of extracellular ATP on the growth of nasopharyngeal carcinoma cells via P2Y2 receptor and osteopontin

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Yang, Guang ^a   Zhang, Shenghong ^b   Zhang, Yanling ^c   Zhou, Qiming ^a   Peng, Sheng ^a   Zhang, Tao ^a   Yang, Changfu ^d   Zhu, Zhenyu ^d   Zhang, Fujun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Extracellular ATP; Nasopharyngeal carcinoma; Osteopontin; P2Y2 receptor

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; CASPASE 3; OSTEOPONTIN; PROTEIN BAX; PURINERGIC P2Y2 RECEPTOR; SYNAPTOTAGMIN I;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL FRACTIONATION; CELL MIGRATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LUCIFERASE ASSAY; MTT ASSAY; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; UPREGULATION; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; CALCIUM SIGNALING; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION; HUMANS; NASOPHARYNGEAL NEOPLASMS; OSTEOPONTIN; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PURINERGIC P2Y2; TRANSCRIPTION FACTOR RELA;

EID: 84903836272     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-53     Document Type: Article

References (40)

1. Purinergic signaling during inflammation. Eltzschig HK, Sitkovsky MV, Robson SC, N Engl J Med 2012 367 24 2322 2333
2. Receptors for purines and pyrimidines. Ralevic V, Burnstock G, Pharmacol Rev 1998 50 3 413 492 (Pubitemid 28477681)
3. Higher concentrations of extracellular ATP suppress proliferation of Caco-2 human colonic cancer cells via an unknown receptor involving PKC inhibition. Yaguchi T, Saito M, Yasuda Y, Kanno T, Nakano T, Nishizaki T, Cell Physiol Biochem 2010 26 2 125 134
4. Extracellular nucleotides inhibit growth of human oesophageal cancer cells via P2Y(2)-receptors. Maaser K, Hopfner M, Kap H, Sutter AP, Barthel B, von Lampe B, Zeitz M, Scherubl H, Br J Cancer 2002 86 4 636 644 (Pubitemid 34185104)
5. An in vivo model of melanoma: treatment with ATP. White N, Knight GE, Butler PE, Burnstock G, Purinergic Signal 2009 5 3 327 333
6. Cell death induced by uridine 5′-triphosphate (UTP) in contrast to adenosine 5′-triphosphate (ATP) in human epidermoid carcinoma cells (A-431). Volkl T, Ogilvie A, Neuhuber W, Ogilvie A, Cell Physiol Biochem 2008 22 5-6 441 454
7. Purinoceptors: are there families of P2X and P2Y purinoceptors? Abbracchio MP, Burnstock G, Pharmacol Ther 1994 64 3 445 475 (Pubitemid 24381231)
8. P2X receptors in sensory neurones. Burnstock G, Br J Anaesth 2000 84 4 476 488 (Pubitemid 30166657)
9. A retrospective of recombinant P2Y receptor subtypes and their pharmacology. Sak K, Webb TE, Arch Biochem Biophys 2002 397 1 131 136 (Pubitemid 34848258)
10. International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P, Voigt M, Humphrey PP, Pharmacol Rev 2001 53 1 107 118 (Pubitemid 32173110)
11. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Dubyak GR, El-Moatassim C, Am J Physiol 1993 265 3 Pt 1 577 C606
12. P2Y2 receptor inhibits EGF-induced MAPK pathway to stabilise keratinocyte hemidesmosomes. Faure E, Garrouste F, Parat F, Monferran S, Leloup L, Pommier G, Kovacic H, Lehmann M, J Cell Sci 2012 125 Pt 18 4264 4277
13. P2Y2 receptor-mediated lymphotoxin-alpha secretion regulates intercellular cell adhesion molecule-1 expression in vascular smooth muscle cells. Seye CI, Agca Y, Agca C, Derbigny W, J Biol Chem 2012 287 13 10535 10543
14. P2Y2 receptor activates nerve growth factor/TrkA signaling to enhance neuronal differentiation. Arthur DB, Akassoglou K, Insel PA, Proc Natl Acad Sci USA 2005 102 52 19138 19143 (Pubitemid 43049579)
15. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, Lysiak JJ, Harden TK, Leitinger N, Ravichandran KS, Nature 2009 461 7261 282 286
16. Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. Chen Y, Liu H, Wu W, Li Y, Li J, J Exp Clin Cancer Res 2013 32 45
17. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, Kraynov E, J Exp Clin Cancer Res 2012 31 26
18. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L, Hepatology 2012 55 2 483 490
19. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, Ren N, Qin LX, Hepatology 2008 48 6 1834 1842
20. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. Lin YH, Yang-Yen HF, J Biol Chem 2001 276 49 46024 46030
21. CREB mediates UTP-directed arterial smooth muscle cell migration and expression of the chemotactic protein osteopontin via its interaction with activator protein-1 sites. Jalvy S, Renault MA, Lam SLL, Belloc I, Reynaud A, Gadeau AP, Desgranges C, Circ Res 2007 100 9 1292 1299 (Pubitemid 46742919)
22. Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. Cheng J, Huo DH, Kuang DM, Yang J, Zheng L, Zhuang SM, Cancer Res 2007 67 11 5141 5147 (Pubitemid 46997250)
23. Osteopontin regulates growth and migration of human nasopharyngeal cancer cells. Yang G, Zhang Y, Wu J, Xiong J, Deng H, Wang J, Yang C, Zhu Z, Mol Med Rep 2011 4 6 1169 1173
24. Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells. Kim MS, Park MJ, Moon EJ, Kim SJ, Lee CH, Yoo H, Shin SH, Song ES, Lee SH, Cancer Res 2005 65 3 686 691 (Pubitemid 40216422)
25. Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Zhang G, He B, Weber GF, Mol Cell Biol 2003 23 18 6507 6519 (Pubitemid 37075762)
26. Hepatocyte growth factor increases osteopontin expression in human osteoblasts through PI3K, Akt, c-Src, and AP-1 signaling pathway. Chen HT, Tsou HK, Chang CH, Tang CH, PLoS One 2012 7 6 38378
27. Resveratrol-mediated apoptosis of hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation. Frazzi R, Valli R, Tamagnini I, Casali B, Latruffe N, Merli F, Int J Cancer 2013 132 5 1013 1021
28. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Kolfschoten GM, Hulscher TM, Pinedo HM, Boven E, Br J Cancer 2000 83 7 921 927
29. Extracellular ATP activates multiple signalling pathways and potentiates growth factor-induced c-fos gene expression in MCF-7 breast cancer cells. Wagstaff SC, Bowler WB, Gallagher JA, Hipskind RA, Carcinogenesis 2000 21 12 2175 2181 (Pubitemid 32049223)
30. Feed forward cycle of hypotonic stress-induced ATP release, purinergic receptor activation, and growth stimulation of prostate cancer cells. Nandigama R, Padmasekar M, Wartenberg M, Sauer H, J Biol Chem 2006 281 9 5686 5693 (Pubitemid 43847666)
31. Blockage of volume-activated chloride channels inhibits migration of nasopharyngeal carcinoma cells. Mao J, Wang L, Fan A, Wang J, Xu B, Jacob TJ, Chen L, Cell Physiol Biochem 2007 19 5-6 249 258 (Pubitemid 46701500)
32. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Packer L, Pavey S, Parker A, Stark M, Johansson P, Clarke B, Pollock P, Ringner M, Hayward N, Carcinogenesis 2006 27 9 1778 1786 (Pubitemid 44288660)
33. Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Wong TS, Kwong DL, Sham J, Wei WI, Kwong YL, Yuen AP, Eur J Surg Oncol 2005 31 5 555 558 (Pubitemid 40724099)
34. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Hui EP, Sung FL, Yu BK, Wong CS, Ma BB, Lin X, Chan A, Wong WL, Chan AT, Clin Cancer Res 2008 14 21 7080 7087
35. Silencing of P2Y2 receptor delays Ap4A-corneal re-epithelialization process. Crooke A, Mediero A, Guzman-Aranguez A, Pintor J, Mol Vis 2009 15 1169 1178
36. G alpha(q/11)-coupled P2Y2 nucleotide receptor inhibits human keratinocyte spreading and migration. Taboubi S, Milanini J, Delamarre E, Parat F, Garrouste F, Pommier G, Takasaki J, Hubaud JC, Kovacic H, Lehmann M, FASEB J 2007 21 14 4047 4058 (Pubitemid 350232361)
37. Nuclear factor-kappaB in cancer development and progression. Karin M, Nature 2006 441 7092 431 436 (Pubitemid 44050137)
38. Targeting 3-phosphoinositide-dependent protein kinase 1 by N-acetyl-cysteine through activation of peroxisome proliferators activated receptor alpha in human lung cancer cells, the role of p53 and p65. Hann SS, Zheng F, Zhao S, J Exp Clin Cancer Res 2013 32 43
39. The antitumor effect of a novel angiogenesis inhibitor (an octahydronaphthalene derivative) targeting both VEGF receptor and NF-kappaB pathway. Watari K, Nakamura M, Fukunaga Y, Furuno A, Shibata T, Kawahara A, Hosoi F, Kuwano T, Kuwano M, Ono M, Int J Cancer 2012 131 2 310 321
40. Extracellular nucleotide inhibits cell proliferation and negatively regulates Toll-like receptor 4 signalling in human progenitor endothelial cells. Xiao Z, Yang M, Fang L, Lv Q, He Q, Deng M, Liu X, Chen X, Chen M, Xie X, Hu J, Cell Biol Int 2012 36 7 625 633